hyperCORE Welcomes New Partner for Enhanced Clinical Research
hyperCORE International is thrilled to announce its collaboration with Atlas Clinical Research, further bolstering its network of partner sites. This partnership marks a significant step in expanding the organization's outreach and capabilities in clinical research.
Atlas Clinical Research: A Partner with Vision
Atlas Clinical Research is designed with a focus on therapeutic expertise and operational excellence. Their site network integrates advanced technologies, allowing them to effectively connect patients and their families to new and potentially life-altering treatments. Atlas emphasizes key areas such as infectious diseases, central nervous system, gastroenterology, cardiovascular health, metabolic conditions, and general medicine. The goal is to ensure a broad reach throughout various regions to provide access to a diverse population of patients eager for new health solutions.
Patient-Centered Approach
Atlas is dedicated to improving patient care by forming close partnerships with biopharmaceutical sponsors and contract research organizations (CROs). The organization’s focus on fast-tracking healthcare advancements enables them to streamline clinical trial processes, ensuring faster patient access to innovative therapies. Their commitment to quality data, effective patient care, and operational speed distinguishes them within the clinical research arena.
Benefits of the Partnership
The addition of Atlas to hyperCORE’s network enhances the collective strength available to clinical trials. As stated by Rajat Mayur, Chief Commercial Officer of Atlas, the strategic alignment with hyperCORE allows for the delivery of high-quality clinical trial execution. This collaboration is expected to simplify the site selection process for sponsors, thereby facilitating a dependable and effective trial environment.
Leadership Perspectives
Carlos Orantes, President of hyperCORE and CEO of its partner site network Alcanza Clinical Research, expressed excitement about the partnership. He highlighted that hyperCORE now provides centralized access to over 150 high-performing sites, further enriching its value proposition for sponsors and CROs. This collaboration with Atlas, under the leadership of Mark Scullion and Raj Mayur, is set to enhance the overall offering to all clinical stakeholders involved.
About hyperCORE International
hyperCORE International stands as a leading partner site network, comprised of award-winning clinical research entities recognized for their excellence in Phase I through IV clinical trial services. With more than 125 active research sites across two continents and five countries, hyperCORE is instrumental in executing a wide range of studies. The organization’s alliance partners bring decades of independent operational experience, contributing to the completion of over 7,000 clinical studies involving upwards of 150,000 randomized patients.
This strategic collaboration not only streamlines clinical processes but also empowers research facilities to share best practices, thereby ensuring research excellence, patient safety, data integrity, prompt study commencement, competitive enrollment strategies, and superb retention rates.
Frequently Asked Questions
What is the main objective of hyperCORE's partnership with Atlas Clinical Research?
The main objective is to expand hyperCORE's network and enhance clinical research capabilities, improving patient access to innovative treatments.
What areas does Atlas Clinical Research specialize in?
Atlas specializes in infectious diseases, CNS, gastroenterology, cardiovascular, metabolic conditions, and general medicine.
How many sites are included in hyperCORE's network?
hyperCORE's network includes over 125 active research sites globally.
What benefits do sponsors gain from this partnership?
Sponsors gain streamlined access to a network of high-performing sites, accelerating the clinical trial process and improving data quality and patient care.
Who leads Atlas Clinical Research?
Atlas Clinical Research is led by Rajat Mayur as the Chief Commercial Officer and Mark Scullion, enhancing its collaborative operations.
